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A new candidate mutation, G1629R, in a patient
with type 2A von Willebrand’s disease:
basic mechanisms and clinical implications
Von Willebrand factor (VWF) is a largeadhesive glycoprotein that plays acritical role in the early phases of
hemostasis. It protects factor VIII (FVIII)
from proteolytic degradation in the circu-
lation and mediates platelet adhesion at
the sites of vessel injury.1 VWF, synthesized
by endothelial cells and megakaryocytes as
a 2,813 amino acid pre-pro-polypeptide, is
modified by post-translational processing
including propeptide (amino acids 23-763)
cleavage and multimerization.2 Thus, VWF
circulates in plasma as a series of disul-
phide-linked multimers ranging from 0.5 to
over 107 daltons. Some plasma VWF sub-
units appear to be modified by ADAMTS-
13, which induces a specific proteolytic
cleavage between amino acid residues
Y1605 and M1606 in the A2 domain.
VWF defects result in von Willebrand’s dis-
ease (VWD), the most common inherited
bleeding disorder in humans. This disorder
can result from either a quantitative (types 1
and 3) or qualitative (type 2) defect in VWF.
Patients with type 2A VWD have decreased
VWF platelet-dependent function associated
with the absence of high molecular weight
(HMW) VWF multimers.3 Most of the muta-
tions responsible for this sub-type have been
identified in the A2 domain clustered within
the 134 amino acid sequence from G1505 to
E1638 (http://www. sheffield.ac.uk/vwf).
Expression of recombinant VWF (rVWF) con-
taining these mutations has elucidated two
pathogenic mechanisms leading to the char-
acteristic loss of HMW multimers in plasma
VWF.4 Group 1 type 2A VWD mutations
impair the biosynthesis and/or secretion of
VWF multimers and lead to the retention of
mutated VWF in the endoplasmic reticulum
and subsequent decrease in large and inter-
mediate VWF forms in both plasma and
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Background and Objectives. Type 2A von Willebrand’s disease (VWD) refers to disease
variants with decreased platelet-dependent function of von Willebrand factor (VWF)
associated with the absence of high molecular weight (HMW) multimers. The candidate
G1629R mutation, identified in an Italian patient with type 2A VWD, was expressed to
confirm the relationship between phenotype and genotype.
Design and Methods. Plasma samples from the patient were studied after 1-deamino-
8-D-arginine vasopressin (DDAVP) or FVIII/VWF concentrate injections. Furthermore, an
expression vector carrying the G1629R mutation was constructed by site-directed muta-
genesis and transiently expressed in Cos-7 cells. The characteristics of the corresponding
recombinant protein were analyzed. 
Results. After DDAVP infusion, factor VIII and VWF activities increased and HMW VWF
multimers were transiently observed in the patient’s plasma. VWF activity increased only
after administration of a dual FVIII/VWF concentrate.  ADAMTS-13 activity did not change
significantly before or after the therapies. Secretion, in culture medium, of the correspon-
ding mutated protein (R1629-rVWF) was slightly decreased and this rVWF contained
intermediate and HMW multimers. Furthermore, binding of R1629-rVWF to platelet GPIb
was moderately reduced compared to that of the wild-type rVWF. 
Interpretation and Conclusions. Based on the DDAVP and in vitro expression results,
we classified the G1629R mutation in group 2 type 2A mutations. Our findings could
explain why DDAVP may only be partially effective and suggest that FVIII/VWF concen-
trates should be used in cases of prolonged mucosal bleeding and major surgery when
functional VWF is required.
Key words: von Willebrand factor, von Willebrand’s disease, mutation, recombinant
protein, Cos-7 cells.
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platelets. In group 2 type 2A VWD, VWF is normally
processed and secreted but is more sensitive to prote-
olysis and thus the levels of HMW VWF multimers in
plasma are decreased. Platelet VWF in patients belong-
ing to this group is protected from plasma protease and
is, therefore, normal. Furthermore, Englender et al.5 have
shown that the V1665E mutation represents a new
group of type 2A mutations characterized by a striking
degree of intracellular proteolysis.
We report here the phenotypic data from an Italian
patient with type 2A VWD, characterized by a muta-
tion changing glycine 1629 into arginine (G1629R). To
understand this VWF defect better, VWF activities were
measured before and after infusion of 1-deamino-8-
D-arginine vasopressin (DDAVP) and transfusion of a
plasma-derived dual FVIII/VWF concentrate.  The phe-
notypic data of the patient were compared with those
obtained in vitro for the recombinant mutant VWF
obtained after site-directed mutagenesis and transient
expression in Cos-7 cells. Both ex vivo and in vitro data
suggest that the G1629R mutation can be classified in
group 2 type 2A mutations.
Design and Methods
Clinical and phenotypic characterization of the
patient
This study was performed in an Italian patient with
type 2A VWD diagnosed at the Angelo Bianchi Bonomi
Hemophilia Thrombosis Center of Milan, also included
in the European project entitled Optimizing Orphan
Drug Therapy in Severe Forms of VWD.6
The patient had a negative family history but a life-
long personal history of epistaxis, gum and gastroin-
testinal bleeding and bleeding after dental extractions.
Minor bleeding problems had been solved in the past
using DDAVP. However, large doses of intermediate
purity FVIII/VWF concentrates were necessary to stop
gastrointestinal bleeding and prevent hemorrhage dur-
ing major surgery. Because of previous transfusions
received in the 1970s and 1980s, the patient has a
degree of liver cirrhosis caused by hepatitis C virus
infection.
The patient’s bleeding time (BT) was measured using
a commercially available device that makes two stan-
dard 1 mm horizontal skin incisions in the volar region
of the forearm (Simplate IIR, BioMérieux, Inc, Durham,
NC, USA). Factor VIII activity (FVIII:C) was evaluated
using the pro-coagulant activity test (the one stage
assay) derived from an activated partial thromboplas-
tin time (APTT) assay in FVIII-depleted plasma (Hemo-
liance) by using Electra 1600 Coagulometer produced
by Instrumentation Laboratories (IL, Lexington, MA,
USA). The reagent for APTT is SyntAsil (Hemoliance)
which is also distributed by Instrumentation Laborato-
ries. VWF antigen (VWF:Ag) (ELISA), VWF ristocetin
cofactor activity (VWF:RCo) (by agglutination) and VWF
collagen binding capacity (VWF:CB) (ELISA) were deter-
mined as described in a recent report.7 Platelet VWF
was measured as described elsewhere.8 Multimeric
analysis of plasma VWF was performed using sodium
dodecyl sulfate (SDS) agarose (1.2% or 1.6%) elec-
trophoresis.9 The gels were scanned and the resulting
densitometric profiles were used to calculate the per-
centage of HMW VWF multimers (> 10 mers). The ris-
tocetin-dependent platelet binding assay on patient’s
plasma VWF was performed as previously reported.10 In
order to determine the biological response to DDAVP,
the patient, after having signed informed consent and
when not bleeding, was given a 0.3 µg/kg i. v. infusion
of DDAVP under medical supervision. Venous blood was
collected at specific times (before, 0.5, 1, 2 and 4 hours
after the infusion) according to the standardized pro-
tocol.6 More recently, we also had the opportunity to
measure FVIII/VWF and BT after administration of a
plasma-derived dual FVIII/VWF concentrate (Alphanate,
Alpha-Therapeutics). The patient had not bled during
the previous 15 days and was given 40 U/kg of
Alphanate before a single dental extraction. To compare
data with those collected during the DDAVP trial, blood
samples were taken before and 1, 2, and 4 hours after
administration of this concentrate. Finally, to determine
whether the VWF cleaving protease, ADAMTS-13, was
affecting the patient’s VWF, we measured ADAMTS-13
activity before and after both therapies according to a
method already published.11
Detection and expression of VWF molecular
abnormality
Exon 28 of the patient’s VWF gene was amplified by
polymerase-chain reaction (PCR) and sequenced (Geno-
screen, Institut Pasteur, Lille, France). A mutated vector
containing the G1629R substitution was constructed
in a pSVVWFA vector12 using the Transformer site-
directed mutagenesis kit according to the manufactur-
er’s instructions (Invitrogen Life Technologies). After
verifying that no undesired mutations were present, the
mutated Not I-Nhe I fragment [nucleotide (nt) 2974-
5209] was sub-cloned into a normal expression vector.
Wild type (WT) and mutated expression vectors were
transiently transfected into Cos-7 cells using the
diethylaminoethyl dextran method as previously
described.13 Expression was performed in the presence
of 10% (V/V) fetal bovine serum (Invitrogen Life Tech-
nologies). Culture medium containing rVWF was col-
lected in the presence of 10 mM benzamidine and 1
mM phenylmethylsulfonyl fluoride (PMSF) and cleared
from cellular fragments by centrifugation for 5 min-
utes at 2,500 g. The cell lysate was reconstituted in 1
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mL lysis buffer (150 mM NaCl, 10 mM Tris-HCl pH 8.0,
5 mM EDTA, 1% Nonidet P-40, 2 mM N-ethyl-
maleimide, 10 mM benzamidine, 1 mM PMSF) and cen-
trifuged at 2,500 g for 5 minutes before use. 
rVWF analysis
rVWF in the media and in cell lysates from transfect-
ed cells was quantified by ELISA.13 The multimeric com-
position of rVWF was analyzed in 1.5% agarose gels in
the presence of 0.1% SDS and the VWF multimers were
visualized with alkaline phosphatase-conjugated anti-
VWF polyclonal antibodies.13 Ristocetin-dependent
platelet binding assays were performed as previously
reported.10
Results
Patient’s phenotypic data
The BT with FVIII/VWF and activity of ADAMTS-13
were measured on two different occasions: before and
after DDAVP (Table 1) and before and after a FVIII/VWF
concentrate (Table 2). At baseline, the patient showed
normal FVIII:C and VWF:Ag levels but a low VWF:RCo/Ag
ratio (0.3) with even lower values of VWF:CB/Ag (0.04).
A decrease in HMW and intermediate molecular weight
plasma VWF multimers was observed by agarose gel
electrophoresis (Figure 1A) with an increase in the inten-
sity of the flanking bands in the triplet structure (Figure
1B). There was almost no binding of plasma VWF to GPIb
(Figure 2), in agreement with the very abnormal (>2.5
mg/mL ristocetin) ristocetin-induced platelet aggrega-
tion (RIPA) in the patient’s platelet-rich plasma (not
shown). The platelet VWF content was relatively normal
with VWF:Ag and VWF:RCo values being 0.75  and 0.33
IU/109 platelets, respectively.
One hour after DDAVP infusion, the patient’s VWF:Ag
level had increased to 236 IU/dL, and the VWF:RCo activ-
ity had increased to 79 IU/dL (Table 1). These levels
remained almost constant 4 hours after infusion. The BT
shortened from > 30 minutes to 10 minutes, 1 hour post-
infusion but was again very prolonged 4 hours after the
injection (Table 1). The VWF:CB, already lower than
VWF:RCo at baseline, remained always lower following
Table 1. Factor VIII/VWF and ADAMTS-13 activities of the patient before and after DDAVP infusion. 
BT VWF:Ag VWF: VWF: VWF: VWF: ADAMTS-13 (*) FVIII:C
(min) (IU/dL) RCo CB (*) RCo/Ag CB/Ag (IU/dL) (IU/dL)
(IU/dL) (IU/dL) ratio ratio
Before > 30 100 30 4 0.30 0.04 44 61
infusion
0.5 hr n. d. 190 67 18 0.35 0.25 n. d. 192
post-infusion
1 hr 10 236 79 26 0.33 0.19 32 203
post-infusion
2 hr 20 232 60 25 0.26 0.11 38 203
post-infusion
4 hr > 30 252 62 15 0.25 0.06 39 163
post-infusion
*Note that VWF:CB and ADAMTS-13 were measured more recently, in frozen samples.
Table 2. Factor VIII/VWF and ADAMTS-13 activities of the patient before and after exogenous VWF given by 40 U/kg
of a dual  FVIII/VWF concentrate (Alphanate).
BT VWF:Ag VWF: VWF: VWF: VWF: ADAMTS-13 FVIII:C
(min) (IU/dL) RCo CB RCo/Ag CB/Ag (IU/dL) (IU/dL)
(IU/dL) (IU/dL) ratio ratio
Before > 30 84 26 3 0.31 0.04 48 91
infusion
1 hr n. d. 170 107 88 0.63 0.52 43 175
post-infusion
2 hr 8 180 80 67 0.44 0.37 52 156
post-infusion
4 hr n. d. 174 72 55 0.41 0.32 56 151
post-infusion
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DDAVP. HMW multimers were immediately released into
the plasma following infusion, as indicated by a normal
plasma VWF multimeric structure observed 0.5 hour
post-infusion (Figure 1A). However, this effect was only
transient as the VWF multimeric pattern was again
abnormal 2 hours post-infusion.
The administration of exogenous VWF in a high-puri-
ty dual FVIII/VWF concentrate shortened the BT at two
hours (8 min) and normalized both VWF:RCo and
VWF:CB (Table 2). The levels of ADAMTS-13 activity were
at the lowest limit of normal range (44 and 48%). They
decreased slightly just after both treatments and then
ranged between 38 and 56%. (Tables 1 and 2).
Identification of the patient’s molecular
abnormality
Sequencing of PCR-amplified exon 28 of the patient’s
DNA revealed the presence of a cytosine in addition to
the normal guanine at nt 4885. The sequencing profile
therefore indicated that the patient was heterozygous
for this nt change, resulting in the substitution of an
arginine residue for glycine at position 1629 in pre-pro
VWF (mutation G1629R). 
Expression and characterization of rVWF
Cos-7 cells were transiently transfected with WT or
R1629 plasmids (6 transfections of 2 different clones).
The levels of mutated rVWF present in the culture media
and in the corresponding transfected Cos-7 cell lysates
were slightly lower than the levels of the WT-rVWF
obtained in the same transfection experiments (78±18%
and 77±20%, respectively).  As shown in Figure 3A, the
multimeric profile of the mutated rVWF present in cul-
ture media showed that all multimers were present
although a slight decrease in the highest molecular
weight multimers was observed. The multimeric struc-
ture in the corresponding cell lysates was similar to that
of WT-rVWF. Mutated rVWF showed a moderately weak-
eNED capacity for binding to platelets, when compared
to WT-rVWF (Figure 3B).
Figure 1. Multimeric structure of plasma VWF in SDS-1.2% agarose gel (A) or SDS-1.6% agarose gel (B). Numbers
correspond to the various multimers of the VWF protomer. Arrows indicate VWF satellite bands that are increased
in the patient’s plasma. NP: normal plasma. The percentage of HMW multimers above 10-mers, determined by den-
sitometric scanning, is indicated below each lane.
Figure 2. Ristocetin-induced binding of normal plasma
(P) or patient’s plasma (p) VWF to platelets. 
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Discussion 
We report here the case of an Italian VWD patient
who has a low VWF:RCo/Ag and VWF:CB/Ag ratio, loss
of high and intermediate molecular weight plasma
VWF multimers and no ristocetin-induced binding of
plasma VWF to platelets. The fact that both VWF:RCo
and VWF:CB activities were abnormal together with
the relative loss of HMW multimers in this patient
immediately suggested a type 2A and not a type 2M
VWD defect.14 The platelet VWF content was relative-
ly normal, even though VWF:RCo was lower than
VWF:Ag. These VWF abnormalities could be responsi-
ble for the very prolonged BT observed on different
occasions. Unfortunately, we could not test the PFA-
100 in this particular patient; however, in our hands,
PFA-100 has correlated very well with BT in other cas-
es of type 2A VWD.15 Physiologic proteolysis of endoge-
nous VWF is regulated by plasma levels of ADAMTS-
13.16 In our patient, the baseline level of ADAMTS-13
was borderline, probably because of abnormal liver
function.11 There was a slight and transient reduction
of ADAMTS-13 activity after the increase of endoge-
nous (DDAVP) or exogenous (FVIII/VWF concentrate)
VWF, as recently reported by several authors.17,18 This
patient responded only transiently to DDAVP as indi-
cated by correction of BT, doubling of VWF levels and
appearance of HMW multimers in plasma 1 hour post-
infusion. However, the BT was again very prolonged
after 2-4 hours, consistent with the relative loss of
HMW multimers in plasma. Conversely, the use of a
high purity FVIII/VWF concentrate improved both
VWF:RCo and VWF:CB activities and  almost correct-
ed the BT also after two hours. This suggests that a
FVIII/VWF concentrate must be recommended in
severe bleeding episodes and for major surgery in such
patients.
After sequencing the VWF exon 28, the G1629R sub-
stitution was identified in the heterozygous state. This
mutation had been previously reported in a Spanish
family and classified as type 2A VWD.19 The Spanish
patient was found to be responsive to DDAVP. Howev-
er, although he showed a discrepancy between VWF:Ag
(31±14 IU/dL) and VWF:RCo (4±1 IU/dL) levels, these
levels were lower than those in our Italian patient. 
Four relatives of the Spanish patient  were reported
to bleed excessively after surgical surgery and dental
extractions. Despite the relatively higher values of FVI-
II/VWF activities, the Italian patient had a history of
very severe bleeding: minor bleedings and surgery had
been treated successfully with DDAVP but recurrent
episodes of gastrointestinal bleeding and major sur-
gery (e.g. colectomy) had required extensive infusions
of FVIII/VWF concentrates. Nevertheless, improvement
of VWF levels and hemostasis after DDAVP treatment
observed in the propositi of both families suggest that
the G1629R mutation is compatible with normal mul-
timerization but could induce increased sensitivity of
VWF to extracellular proteolysis. 
To confirm the effect of this mutation on the
patient’s phenotype, full length cDNA carrying the
G1629R mutation was transiently expressed in Cos-7
cells. The corresponding secreted rVWF contained well
Figure 3. Multimeric structure of rVWF present in
culture media or cell lysates after 1.5% agarose
gel electrophoresis (A) and ristocetin-induced
binding of WT-rVWF (P) or R1629-rVWF (p) to
platelets (B). 
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multimerized multimers although some HMW multi-
mers were decreased, probably related to proteases
known to be present in fetal bovine serum. Mutated
rVWF present in cell lysates was normal. Binding of
secreted R1629-rVWF to platelets was moderately
decreased. The results therefore resemble data
obtained with the R1597W mutation (a type 2A-group
2 mutation) which induced a normal multimeric pat-
tern of corresponding rVWF although ristocetin-
induced binding to platelets was decreased.20 The fact
that the R1629-rVWF binding to GPIb was moderate-
ly decreased whereas the patient’s VWF binding was
almost nil suggests that the functional abnormality of
the plasma VWF is the result of the combined effects
of both the mutation and the disappearance of HMW
multimers.
Using molecular modeling, Jenkins et al.21 showed
that type 2A VWD mutation sites in the A2 domain
correspond to buried residues that are otherwise 100%
conserved across 28 species analyzed. The glycine
residue at position 1629 is also conserved across these
28 species confirming that a precise conformation in
this area is required for correct protein structure and
function. The G1629R mutation may expose a region
on the surface of the protein, resulting in an increased
susceptibility of VWF to plasma proteases. 
In conclusion, the laboratory data from our patient
with a specific mutation within exon 28 of the VWF
gene are not only important for understanding the
basic mechanisms of type 2A VWD but can also help
to define the most appropriate clinical management.
In fact, the data show that DDAVP may be only par-
tially effective, especially for prolonged mucosal bleed-
ing episodes and after major surgery. These phenotyp-
ic and expression data strongly support the use of con-
centrates containing VWF in type 2A VWD patients in
such clinical settings.
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